# AstraZeneca agrees to sell the rights to Crestor in over 30 countries in Europe

- Link: https://www.directorstalkinterviews.com/astrazeneca-agrees-to-sell-the-rights-to-crestor-in-over-30-countries-in-europe/412942945
- Published: 2020-12-01T07:22:03+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has agreed to sell the rights to _Crestor _(rosuvastatin) and associated medicines
in over 30 countries in Europe, except the UK and Spain, to Grünenthal GmbH (Grünenthal).
_Crestor_ is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia.

AstraZeneca will continue to manufacture and supply _Crestor_ to Grünenthal during
a transition period. AstraZeneca will also continue selling the medicine in other
countries, including those in North America, in Japan, China and other emerging 
markets.

**Financial considerations**

The divestment is anticipated to close in the first quarter of 2021, subject to 
customary closing conditions and regulatory clearances, upon which Grünenthal will
make an upfront, non-contingent payment to AstraZeneca of $320m and may also make
future milestone payments of up to $30m. Income arising from the upfront and future
payments will be reported in AstraZeneca’s financial statements within Other Operating
Income & Expense. The divestment will not impact the Company’s financial guidance
for 2020.

Pursuant to London Stock Exchange listing rule 10.4.1R (notification of class 2 
transactions), the gross book value of assets subject to the divestment as of 31
December 2019 was nil. In 2019, _Crestor_ generated Product Sales of $136m and Profit
before Tax of $98m in the countries covered by the agreement. The consideration 
will be paid in cash and the proceeds used for general corporate purposes.

**Crestor**

_Crestor_ (rosuvastatin) is a statin, a lipid-lowering medicine, used to treat blood
lipid disorders and to prevent cardiovascular events, such as heart attacks and 
strokes. _Crestor_ produces its lipid modifying effects in two ways: it blocks an
enzyme in the liver causing the liver to make less cholesterol, and it increases
the uptake and breakdown by the liver of cholesterol already in the blood. _Crestor_
is approved as a lipid regulating medicine in more than 100 countries.

> **Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said:**“
> This agreement supports the management of our mature medicines to enable reinvestment
> into the pipeline and bringing new, innovative treatments to patients. Grünenthal
> previously acquired the rights to several established AstraZeneca medicines and
> is well placed to ensure continued access to _Crestor_ for patients across Europe.”

Share on:
